FY2025 EPS Estimates for ACRS Decreased by Cantor Fitzgerald

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of Aclaris Therapeutics in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will post earnings of ($0.62) per share for the year, down from their previous estimate of ($0.54). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

A number of other equities analysts have also issued reports on the stock. HC Wainwright upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Monday, December 23rd. StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 8th. Finally, Scotiabank began coverage on shares of Aclaris Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

Aclaris Therapeutics Stock Up 1.9 %

ACRS opened at $1.60 on Thursday. Aclaris Therapeutics has a 52 week low of $0.95 and a 52 week high of $5.17. The business’s 50 day moving average is $2.16 and its two-hundred day moving average is $2.20. The firm has a market cap of $172.67 million, a price-to-earnings ratio of -3.08 and a beta of 0.48.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. ExodusPoint Capital Management LP purchased a new stake in shares of Aclaris Therapeutics during the 4th quarter worth $26,000. Invesco Ltd. purchased a new position in shares of Aclaris Therapeutics in the 4th quarter valued at about $28,000. Graham Capital Management L.P. acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at about $35,000. Commonwealth Equity Services LLC purchased a new stake in Aclaris Therapeutics during the fourth quarter worth about $36,000. Finally, Alpine Global Management LLC acquired a new position in Aclaris Therapeutics during the fourth quarter worth about $38,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.